Cargando…

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer

The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy represented a milestone in the treatment of lung cancer over the last years. Tumor genotyping has been incorporated into therapeutic decision making of advanced non-small cell lung cancer (NSCLC) since...

Descripción completa

Detalles Bibliográficos
Autores principales:	Listì, Angela, Barraco, Nadia, Bono, Marco, Insalaco, Lavinia, Castellana, Luisa, Cutaia, Sofia, Ricciardi, Maria Rita, Gristina, Valerio, Bronte, Enrico, Pantuso, Gianni, Passiglia, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799193/ https://www.ncbi.nlm.nih.gov/pubmed/35117064 http://dx.doi.org/10.21037/tcr.2018.10.04

Ejemplares similares

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?
por: Fanale, Daniele, et al.
Publicado: (2015)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code
por: Cammarata, Giuseppe, et al.
Publicado: (2022)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
por: Cheloni, Giulia, et al.
Publicado: (2017)

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
por: Cabibi, Daniela, et al.
Publicado: (2016)

Targeting of non-oncogene addiction
por: Igea, Ana, et al.
Publicado: (2015)

Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review
por: Passiglia, Francesco, et al.
Publicado: (2022)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Oncogene addiction: resetting the safety switch?
por: Li, Yulin, et al.
Publicado: (2014)

BIM-mediated apoptosis and oncogene addiction
por: Li, Yulin, et al.
Publicado: (2016)

Rhabdomyosarcomas are oncogene addicted to the activation of AVIL
por: Xie, Zhongqiu, et al.
Publicado: (2022)

Drugging the addict: non‐oncogene addiction as a target for cancer therapy
por: Nagel, Remco, et al.
Publicado: (2016)

Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
por: La Paglia, Laura, et al.
Publicado: (2017)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
por: Jacobi, Nico, et al.
Publicado: (2017)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Oncogenic addiction to high 26S proteasome level
por: Tsvetkov, Peter, et al.
Publicado: (2018)

Oncogene addiction and immune escape: friends or foes?
por: Abdayem, Pamela, et al.
Publicado: (2020)

Targeting Non-Oncogene Addiction for Cancer Therapy
por: Chang, Hae Ryung, et al.
Publicado: (2021)

Oncogene-like addiction to aneuploidy in human cancers
por: Girish, Vishruth, et al.
Publicado: (2023)

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
por: Virzì, Anna Rita, et al.
Publicado: (2018)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
por: Calabrese, Fiorella, et al.
Publicado: (2022)

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
por: Amin, Amit Dipak, et al.
Publicado: (2015)

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
por: Corrales, Luis, et al.
Publicado: (2017)

Oncogene addiction in gliomas: Implications for molecular targeted therapy
por: Yan, Wei, et al.
Publicado: (2011)

Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
por: Anania, Maria Chiara, et al.
Publicado: (2020)

Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
por: Lee, Matilda, et al.
Publicado: (2018)

Acquisition of chromosome instability is a mechanism to evade oncogene addiction
por: Salgueiro, Lorena, et al.
Publicado: (2020)

Epigenetic modulation reveals differentiation state specificity of oncogene addiction
por: Khaliq, Mehwish, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dup94c4ecaba8rq5de8a7nal2a